Literature DB >> 11882689

Pathophysiological basis of acute inflammatory hyperaemia in the rat knee: roles of cyclo-oxygenase-1 and -2.

Colin G Egan1, John C Lockhart, William R Ferrell, Suzanne M Day, John S McLean.   

Abstract

The role of different isoforms of cyclo-oxygenase (COX) in mediating the acute (0-6 h) and late (24 h) phases of inflammation was investigated in the rat knee joint following intra-articular injection of carrageenan. The hyperaemic response was assessed transcutaneously using laser Doppler imaging (LDI). Samples were taken at corresponding time points for detection of synovial COX-1, COX-2 and inducible nitric oxide synthase (iNOS) mRNA, and measurement of urinary prostaglandin (PG) and nitric oxide metabolites (NO(x)). A non-selective COX inhibitor (indomethacin, 15 mg kg(-1) I.P.), a selective COX-2 inhibitor (SC-236, 16.8 mg kg(-1) I.P.) or vehicle were administered 1 h prior to carrageenan in the acute phase study. LDI scans were taken hourly for 4 h post-induction. Inflammatory hyperaemia in the vehicle group was attenuated in the indomethacin- (P < 0.001, two-way ANOVA) and SC-236-treated groups (P < 0.0001), with no difference between these treatments. At 24 h, I.V. infusion of indomethacin (0.1 mg min(-1)), increased vascular resistance (24 +/- 7.1 %; P < 0.05) compared to vehicle infusion, whereas SC-236 (0.11 mg min(-1)) did not. Resistance changes to indomethacin also differed from SC-236 (P < 0.05). Knee joint diameter progressively increased over 24 h (P < 0.0001, one-way ANOVA). Urinary PG levels increased by 6 h (P < 0.05), but returned to baseline by 24 h. COX-1 mRNA was detectable at all time points; COX-2 mRNA only at 3 h. Urinary NO(x) levels increased progressively over 24 h (P < 0.05), paralleled by induction of iNOS in the 3 and 24 h samples. Prostaglandin production via COX-2 appears to mediate the development of acute inflammatory hyperaemia, but nitrergic mechanisms may supervene subsequently. COX-1 but not COX-2 contributes to the maintenance of basal blood flow in the hyperaemic joint at 24 h.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882689      PMCID: PMC2290144          DOI: 10.1113/jphysiol.2001.013473

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  46 in total

1.  Alteration of NF-kappa B p50 DNA binding kinetics by S-nitrosylation.

Authors:  A DelaTorre; R A Schroeder; P C Kuo
Journal:  Biochem Biophys Res Commun       Date:  1997-09-29       Impact factor: 3.575

2.  Multiple female reproductive failures in cyclooxygenase 2-deficient mice.

Authors:  H Lim; B C Paria; S K Das; J E Dinchuk; R Langenbach; J M Trzaskos; S K Dey
Journal:  Cell       Date:  1997-10-17       Impact factor: 41.582

Review 3.  Nitric oxide in arthritis.

Authors:  D Jang; G A Murrell
Journal:  Free Radic Biol Med       Date:  1998-06       Impact factor: 7.376

4.  COX-2 inhibitors.

Authors:  C J Hawkey
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

5.  Cyclooxygenase isoenzyme localization and mRNA expression in rat lungs.

Authors:  L Ermert; M Ermert; M Goppelt-Struebe; D Walmrath; F Grimminger; W Steudel; H A Ghofrani; C Homberger; H Duncker; W Seeger
Journal:  Am J Respir Cell Mol Biol       Date:  1998-04       Impact factor: 6.914

Review 6.  Nitric oxide and inflammatory joint diseases.

Authors:  D O Stichtenoth; J C Frölich
Journal:  Br J Rheumatol       Date:  1998-03

7.  Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation.

Authors:  J L Wallace; K Chapman; W McKnight
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

8.  Anovulation in cyclooxygenase-2-deficient mice is restored by prostaglandin E2 and interleukin-1beta.

Authors:  B J Davis; D E Lennard; C A Lee; H F Tiano; S G Morham; W C Wetsel; R Langenbach
Journal:  Endocrinology       Date:  1999-06       Impact factor: 4.736

9.  Regulation of cyclooxygenase expression in the kidney by dietary salt intake.

Authors:  T Yang; I Singh; H Pham; D Sun; A Smart; J B Schnermann; J P Briggs
Journal:  Am J Physiol       Date:  1998-03

10.  Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity.

Authors:  J L Wallace; A Bak; W McKnight; S Asfaha; K A Sharkey; W K MacNaughton
Journal:  Gastroenterology       Date:  1998-07       Impact factor: 22.682

View more
  7 in total

1.  Effects of hyaluronan on carrageenan-induced synovitis in rat TMJ.

Authors:  Min-Jung Lee; Kook-Jin Han; Hyuk-Jae Kwon; Han-Sung Jung; Sung-Won Cho
Journal:  Anat Cell Biol       Date:  2010-06-30

2.  Can L(+)-lactate be used as a marker of experimentally induced inflammation in rats?

Authors:  Anja Finn; Sandra Claudine Oerther
Journal:  Inflamm Res       Date:  2009-10-28       Impact factor: 4.575

3.  Pathophysiology of vascular dysfunction in a rat model of chronic joint inflammation.

Authors:  Colin G Egan; John C Lockhart; William R Ferrell
Journal:  J Physiol       Date:  2004-04-02       Impact factor: 5.182

4.  Divergent roles of nitrergic and prostanoid pathways in chronic joint inflammation.

Authors:  S M Day; J C Lockhart; W R Ferrell; J S McLean
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

5.  Anti inflammatory activity of Myrica nagi Linn. Bark.

Authors:  Tejaa Patel; Ashvin Dudhpejiya; Navin Sheath
Journal:  Anc Sci Life       Date:  2011-04

6.  Validation of therapeutic anti-inflammatory potential of Arjuna Ksheera Paka - A traditional Ayurvedic formulation of Terminalia arjuna.

Authors:  Nivedita Dube; Chetan Nimgulkar; Dinesh Kumar Bharatraj
Journal:  J Tradit Complement Med       Date:  2016-12-29

7.  2-Pentadecyl-2-Oxazoline, the Oxazoline of Pea, Modulates Carrageenan-Induced Acute Inflammation.

Authors:  Stefania Petrosino; Michela Campolo; Daniela Impellizzeri; Irene Paterniti; Marco Allarà; Enrico Gugliandolo; Ramona D'Amico; Rosalba Siracusa; Marika Cordaro; Emanuela Esposito; Vincenzo Di Marzo; Salvatore Cuzzocrea
Journal:  Front Pharmacol       Date:  2017-05-30       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.